Tretinoin liposomal - HighField Biopharmaceuticals Corporation
Alternative Names: HF-1K16Latest Information Update: 04 Jul 2025
At a glance
- Originator HighField Biopharmaceuticals
- Class Antiacnes; Antineoplastics; Cyclohexenes; Keratolytics; Retinoids; Small molecules
- Mechanism of Action Myeloid-derived suppressor cell modulators; Protein synthesis inhibitors; Retinoic acid receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase I/II Solid tumours
Most Recent Events
- 25 Apr 2025 Pharmacodynamics and efficacy data from a phase I trial in Solid tumors presented at the 116th Annual Meeting of the American Association for Cancer Research (AACR-2025)
- 16 Sep 2024 HighField Biopharmaceuticals plans a phase II trial for Solid tumours
- 13 Sep 2024 Efficacy data from a phase I trial in Solid tumors presented at the 49th European Society for Medical Oncology Congress (ESMO-2024)